Compare Enveric Biosciences Inc (ENVB) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Nuscale Power Corporation — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Nuscale Power Corporation trades at $7.4 (market cap $3.00B). The key difference: Nuscale Power Corporation is far larger — about 441.2× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 43,143,109). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Nuscale Power Corporation for 29 Days on average.
| ENVB | SMR | |
|---|---|---|
Market Cap | $6.80M | $3.00B |
Volume | 64,867 | 43,143,109 |
Sector | Health | Industrials |
52-Week High | $10.80 | $53.43 |
52-Week Low | $1.27 | $7.32 |
Typical Hold Time | 14 Days | 29 Days |
Enterprise Value | -$1.49M | $1.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
NuScale Power (SMR) trades at $7.67, down 4.42% today, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentally the company faces significant challenges with a net income margin of -3,888.7% and negative cash flow from operations of $459.61 million in 2025. Recent news highlights both the nuclear industry's growth potential and specific challenges facing NuScale, including ongoing legal investigations.
Despite analyst consensus pointing to potential upside with a $11.25 price target, SMR faces substantial execution risks as it burns cash while pursuing commercialization. The company's ability to secure additional financing and achieve revenue growth will be critical for survival, making this a high-risk investment suitable only for investors comfortable with speculative nuclear technology plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
